Page 97 - Read Online

Page 12 of 12 Solimando et al. J Cancer Metastasis Treat 2022;8:9 https://dx.doi.org/10.20517/2394-4722.2021.166

76. Revy P, Kannengiesser C, Fischer A. Somatic genetic rescue in Mendelian haematopoietic diseases. Nat Rev Genet 2019;20:582-98.
DOI PubMed
77. Pasca S, Gondek LP. Clonal hematopoiesis and bone marrow failure syndromes. Best Pract Res Clin Haematol 2021;34:101273. DOI
PubMed PMC
78. Germeshausen M, Ballmaier M, Welte K. Incidence of CSF3R mutations in severe congenital neutropenia and relevance for
leukemogenesis: Results of a long-term survey. Blood 2007;109:93-9. DOI PubMed
79. Leone P, Solimando AG, Malerba E, et al. Actors on the scene: immune cells in the myeloma niche. Front Oncol 2020;10:599098.
DOI PubMed PMC
80. Sugiyama T, Nagasawa T. Bone marrow niches for hematopoietic stem cells and immune cells. Inflamm Allergy Drug Targets
2012;11:201-6. DOI PubMed PMC
81. Hosokawa K, Arai F, Yoshihara H, et al. Function of oxidative stress in the regulation of hematopoietic stem cell-niche interaction.
Biochem Biophys Res Commun 2007;363:578-83. DOI PubMed
82. Solimando AG, Da Vià MC, Leone P, et al. Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on
bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression. Haematologica 2021;106:1943-56.
DOI PubMed PMC
83. Saltarella I, Desantis V, Melaccio A, et al. Mechanisms of resistance to anti-CD38 daratumumab in multiple myeloma. Cells
2020;9:167-80. DOI PubMed PMC
84. Solimando AG, Ribatti D, Vacca A, Einsele H. Targeting B-cell non Hodgkin lymphoma: new and old tricks. Leuk Res 2016;42:93-
104. DOI PubMed
85. Chien KS, Kim K, Nogueras-Gonzalez GM, et al. Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or
higher-risk myelodysplastic syndrome. Br J Haematol 2021;195:378-87. DOI PubMed